baber/WOPTO huggingface dataset:
Patent DE-69422727-D1 (DE)
Inventor: LOGSTON L
IPC: H04J3/16
Filed: 1994-11-03
Granted: 2000-02-24
Abstract: A digital video, audio and data distribution system which enables a set-top terminal (STT) associated with a customer's television set or other information presentation device to request interactive digital video, audio and data services from a service provider (SP) through the use of control system messages transmitted via a hi-directional signalling path. The requested interactive service is transmitted from the service provider over a portion of the bandwidth of a broadband transmission network which is dedicated to interactive digital services. A Video Session Connection (VSC) is provided for setting up and maintaining interactive sessions between the set-top terminal and a video service provider during the time the interactive programming is provided to the customer. The set-top terminal and service provider establish the Video Session Connection via a two-way signalling path within the bandwidth of the transmission medium into the customer's home. Applications of the system of the invention include "movie on demand" services where the set-top terminal not only requests a movie to be transmitted from the service provider for immediate transmission, but also the bi-directional command channel permits the set-top terminal to control the video presentation by sending commands such as Play, Pause, Fast-Forward and the like to the Service Provider while the movie is being transmitted. Other applications of the invention include on-line data retrieval services, shop at home services and other services which require the use of an interactive connection.
Patent DE-69423645-D1 (DE)
Inventor: DEBLANDER JACQUES
IPC: E04B1/86
Filed: 1994-11-09
Granted: 2000-04-27
Abstract: The present invention refers to a multilayered insulating panel or element having (a) two outer facings (1), and (b) a soft synthetic foam core material (2) having hollow profiles (3), connected to both outer facings (1). Also disclosed is a multilayered insulating panel or element having (a) two outer facings (1), and (b) soft core material phases in a spaced relationship between the two outer facings in such a manner that both extremities of the soft core material are contacting the outer facings and having in between such soft core material phases, a second core material having a higher density than the soft core material, wherein only one extremity of each second core material phase contacts only one and the same outer facing. Both types of panel or element possess acoustic insulating properties and mechanical strength.
Patent DE-69431489-D1 (DE)
Inventor: RIEDEL K
IPC: G10L25/93
Filed: 1994-11-02
Granted: 2002-11-07
Abstract: Methods and apparatus for improving the perceived quality of ADPCM encoded signals by magnitude limiting samples of the ADPCM encoded signals prior to the decoding of samples of the ADPCM encoded signals, preferably, a sample of the ADPCM encoded signal is magnitude limited only if a receive error is detected for the sample.
Patent DE-69431545-D1 (DE)
Inventor: GATELY MAURICE KENT
IPC: A61P37/06
Filed: 1994-06-24
Granted: 2002-11-21
Abstract: The present invention is directed towards a protein comprising two p40 subunits of interleukin-12 which are associated together, preferably by at least one disulfide bond, having a molecular weight of about 80 kDa. The 80 kDa p40 homodimer acts as an interleukin-12 receptor antagonist. The preferred p40 subunit is that of SEQ ID NO:1.
Patent DE-69504171-D1 (DE)
Inventor: PAUL JEAN-MICHEL
IPC: B01J31/10
Filed: 1995-12-15
Granted: 1998-09-24
Abstract: In prepn. of isobornyl (meth)acrylate by reaction of (meth)acrylic acid with camphene in presence of a cationic acid ion-exchange resin as catalyst, the (meth)acrylic acid and camphene are stirred together in a stirrer tank, to form a mixt.,which then is contacted with the catalyst in a cartridge separate from the tank. The molar ratio of (meth)acrylic acid: camphene is 4:1-1:4 (2:1-1:2). Reaction is at 10-60 (30-40) degrees C for isobornyl methacrylate and 10-50 (10-30) degrees C for isobornyl acrylate, with a contact time between the resin, swollen in the reaction mixt. at the start of passage of the mixt., of 0.1-10 (1-3) mins.
Patent DE-69512371-D1 (DE)
Inventor: YIN GERALD ZHEYAO
IPC: H05H1/46
Filed: 1995-05-15
Granted: 1999-10-28
Abstract: Plasma generation apparatus, and a related method for its operation, for producing a uniform high-density plasma with good process control and process repeatability. The apparatus includes multipe side electrodes (62.1, 62.6) to which first radio-frequency (rf) power source (57) is connected to provide a transverse electric field for plasma generation, and a pair of convention, upper and lower, electrodes (50, 52) to which a second rf power source (61) is connected to provide separate control of the plasma energy as used in a process such as dry etching. In addition, a magnetic field coil (60) provides a magnetic field perpendicular to the transverse electric field, for enhancement of plasma generation. Because the plasma is generated by a relatively lower frequency (50-200 MHz) power source, as compared with a microwave power source, the magnetic field strength needed to achieve magnetically enhanced operation at or near the electrom cyclotron resonance (ECR) condition is well under 100 gauss, which can be provided at relatively low cost. Moreover, the apparatus can be operated efficiently over a relatively wide range of chamber pressures. Ideally, the number of side electrodes used for plasma generation should be four or six, with each electrode receiving a phase delayed signal as compared with an adjacent electrode, to produce a rotating electric field that further enhances uniformity of plasma formation.
Patent DE-69519523-D1 (DE)
Inventor: STURZA A
IPC: H04B7/195
Filed: 1995-10-10
Granted: 2001-01-04
Abstract: A telecommunications system is disclosed which includes a constellation (10) of satellites (12) equally deployed in four pairs (22) of circular, low Earth orbits (14, 15) inclined at fifty degrees with an interplane phase angle of zero degrees. The system enables two terminals (20) on the ground to communicate through a store-and-forward network.
Patent DE-69523003-D1 (DE)
Inventor: KIISKI ERKKI
IPC: C22C33/02
Filed: 1995-07-05
Granted: 2001-11-08
Abstract: The invention relates to the manufacture of paper machine roll shells of stainless steel. According to the invention, powder is made of molten steel by gas-atomizing, a roll shell preform is made of the powder, and the roll shell preform is machined to form a roll shell. The main advantage of the rolls shells according to the invention is their good corrosion fatigue resistance. <MATH>
Patent DE-69526354-D1 (DE)
Inventor: DAL LAGO ALBERTO
IPC: E04B9/32
Filed: 1995-10-31
Granted: 2002-05-16
Abstract: A prefabricated tile for covering building roofings comprises a plurality of side-by-side light diffusion sites (13) defined by openings (15) provided through a lower flat slab (11) of said tile. From said lower flat slab (11) mutually opposite side walls (12) extend upwards with decreasing height from the middle to the ends of said tile, wherein through said side walls (12) openings (14) are provided to make the whole structure lighter and allow service equipment to run through. <IMAGE>
Patent DE-69530400-D1 (DE)
Inventor: HENDERSON E
IPC: A61K31/167
Filed: 1995-09-19
Granted: 2003-05-22
Abstract: The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.
Patent DE-69530646-D1 (DE)
Inventor: YATES DAVID C
IPC: A61B18/14
Filed: 1995-09-22
Granted: 2003-06-12
Abstract: An impedance monitoring device is provided for monitoring the electrical impedance of tissue as it is treated with electrosurgical energy. Based on a predicted model of tissue impedance and a number of initial impedance readings, the impedance at which tissue treatment is completed is predicted. More particularly, a minimum impedance level is measured and a function of the minimum impedance is used to determine impedance at which coagulation is completed. A control device is provided for bringing the output of the generator within an optimum range based on a system load curve. In one embodiment the impedance monitoring device is used in conjunction with a bipolar electrosurgical instrument. Preferably, the instrument comprises electrically opposite electrodes located on one or more tissue engaging surfaces for engaging tissue to be treated. <IMAGE>
Patent DE-69533004-D1 (DE)
Inventor: COOPER ROBIN DAVID GREY
IPC: A61P31/00
Filed: 1995-01-25
Granted: 2004-06-09
Abstract: A new glycopeptide molecule is inserted into the antibiotic group and both components are mixed with a standard pharmaceutical carrier.
Patent DE-69619536-D1 (DE)
Inventor: ANAND JOGINDER N
IPC: C08K3/04
Filed: 1996-09-12
Granted: 2002-04-04
Abstract: Silicone rubber compositions are disclosed including a silicone polymer and a silicon-treated carbon black. The silicon-treated carbon blacks include a silicon-containing compound that is distributed through at least a portion of the carbon black aggregate. The silicon-treated carbon black is incorporated within a silicone rubber composition as an alternative reinforcing and extending filler, imparting higher hardness to elastomers formed from the composition, when compared to silicone rubber compositions incorporating an untreated carbon black.
Patent DE-69621607-D1 (DE)
Inventor: FINDEIS A
IPC: A61K39/02
Filed: 1996-03-14
Granted: 2002-07-11
Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compounds of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.
Patent DE-69621645-D1 (DE)
Inventor: HUDSON G
IPC: A61K38/06
Filed: 1996-09-11
Granted: 2002-07-11
Abstract: The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1 beta  converting enzyme (ICE).
Patent DE-69624459-D1 (DE)
Inventor: OKAZAKI SHINJI
IPC: C07D401/04
Filed: 1996-08-02
Granted: 2002-11-28
Abstract: A condensed indan derivative represented by the formula (1) <CHEM> wherein the ring A is an optionally substituted benzene ring or a benzene ring which has lower alkylenedioxy group(s), the ring B is an optionally substituted benzene ring or a benzene ring which has lower alkylene dioxy group(s), and R is a group -NR1R2, an optionally substituted nitrogen-containing heterocyclic group, a group -OR3 or a group -SR4 (wherein R1 and R2 are the same or different and each represent a hydrogen atom, a phenyl group, an optionally substituted nitrogen-containing heterocyclic group, or a lower alkyl group which may be substituted by optionally substituted amino group(s), lower alkoxy group(s), phenyl group(s), nitrogen-containing heterocyclic group(s) or hydroxyl group(s), and R3 and R4 each represent a lower alkyl group which may be substituted by substituted amino group(s)), provided that at least one of the rings A and B is a substituted benzene ring and R is not -NHCH3, and salts thereof, and medical use of said derivative and salts.
Patent DE-69626361-D1 (DE)
Inventor: BERTELO CHRIS
IPC: C08L51/08
Filed: 1996-10-24
Granted: 2003-04-03
Abstract: Impact additive of core/shell type consists of 70-90 wt.% core based on alkyl acrylate and 30-10 wt.% shell based on alkyl polymethacrylate or styrene-acrylonitrile copolymer. Cross-linked elastomeric core comprises 20-100 pref. 20-90 wt.% nucleus consisting of copolymer(I) of 5-12C alkyl acrylate or mixt. of 2-12C alkyl acrylates or a polyorganosiloxane rubber, and 0.05-5 wt.% polyfunctional cross-linking agent contg. unsatd. groupings of which at least one is vinylic and, eventually, polyfunctional grafting agent contg. unsatd. groupings of which at least one is allylic; and up to 80 wt.% outer layer consisting of copolymer(II) of 4-12C alkyl acrylate or mixt. of alkyl acrylates as in (I), and 0.05-0.25 wt.% grafting agent with unsaturated groupings of which at least one is allylic. Shell grafted onto core comprises 1-4C alkyl methacrylate polymer, or a statistical copolymer of 1-4C alkyl methacrylate and 1-8C alkyl acrylate contg. 5-40 mol.% alkyl acrylate, or styrene-acrylonitrile copolymer. Also claimed is a compsn. contg. the additive.
Patent DE-69634487-D1 (DE)
Inventor: WILSON MARTIN
IPC: A61K31/662
Filed: 1996-09-24
Granted: 2005-04-21
Abstract: PCT No. PCT/EP96/04161 Sec. 371 Date May 15, 1998 Sec. 102(e) Date May 15, 1998 PCT Filed Sep. 24, 1996 PCT Pub. No. WO97/12619 PCT Pub. Date Apr. 10, 1997The invention relates to a method of treating the navicular disease in horses, which comprises treating the navicular disease in horses with an effective amount of at least one compound of formula (I), wherein R1 is hydrogen, hydroxy, amino or halogen, and R2 is hydrogen, halogen or a radical which is bound through C, N, S or O, or of a C1-C4tetraalkyl ester thereof, each in the free form or in the form of the salt and/or in the hydrate form; to a compound of formula (I) for use in a method of treating the navicular disease, to a composition for use in a method of treating the navicular disease, which comprises one or more than one compound of formula (I), as well as to the use of a compound of formula (I) for the preparation of a veterinary composition for treating the navicular disease.
Patent DE-69635373-D1 (DE)
Inventor: ORBELL ROBIN
IPC: F16K31/20
Filed: 1996-08-02
Granted: 2005-12-08
Abstract: There is described a valve arrangement which in one form is an inlet valve (60) or in another form is a dual flush valve (2). The valves may be used in a variety of situations but find particular application in a cistern for providing water to flush a toilet bowl or similar. The valve arrangement (2) comprises a flushing tube (100) or a pair of flushing tubes  (14, 18) which can move axially. One end of the tubes (100, 18) is sealed to an outlet (9). The tubes are provided with rings or collars (16, 22) which co-operatively engage with locking edges (48, 50) of floats (40, 44) to control movement of the tubes (100, 14, 18). The floats (40, 44) are mounted off-centre or in a position spaced apart from their respective centres of gravity so that they are free to move under the effects of gravity and the effects of lift provided by buoyancy of the floats. In operation the sequential effects of gravity and buoyancy cause the floats to hold the tubes in position and then release the tubes thereby allowing selective flushing positions.
Patent DE-69638173-D1 (DE)
Inventor: NEUWIRTH ROBERT S
IPC: A61P13/02
Filed: 1996-06-06
Granted: 2010-06-10
Abstract: A method and composition for effecting chemical necrosis of a tissue lining of a mammalian body cavity, particularly a uterine endometrium, by delivering a caustic tissue necrosing composition, e.g., a silver nitrate and dextran paste, to the tissue to be necrosed and allowing the paste to remain in contact with the target tissue for a period of time sufficient to chemically necrose substantially the entirety of the tissue lining, and then contacting the caustic composition with a deactivating agent, e.g., an aqueous sodium chloride solution, thereby rendering the caustic composition non-caustic, and then rinsing the cavity. Compositions and methods for delivering medicaments are also disclosed.
Patent DE-69722203-D1 (DE)
Inventor: HOFFSTAETTER THIBAUD
IPC: A61M31/00
Filed: 1997-06-30
Granted: 2003-06-26
Abstract: In an instrument for inserting a suppository, which instrument comprises a tubular housing (31) with a first end adapted to receive said suppository between two tongues (30) and a second end through which a plunger (22) is inserted in the tube, which plunger has a first end having a circular cross section and two axially spaced circumferential flanges (26, 27) and a second end projecting from the second end of the tube (31). The first end of the tube has an inwardly extending shoulder (25) which engage between said flanges (26, 27) and the first end of the piston is by radial slots divided into an uneven number of sectors (29). The plunger (22) has between its first end and a press button (24) at its second end angular spaced radial walls (21) abutting the inner wall of the tube (31) and axial spaced disc shaped walls are provided having a diameter corresponding to the inner diameter of the tube (31).
Patent DE-69729517-D1 (DE)
Inventor: GEERTS ALBERT EMMANUEL CORNEIL
IPC: A61K38/12
Filed: 1997-08-29
Granted: 2004-07-22
Abstract: The invention relates to a pharmaceutical composition for the treatment of fibrosis. According to the invention it was surprisingly found that submicromolar concentrations of a histone deacetylase inhibitor and in particular of trichostatin A strongly inhibit three main features of myofibroblastic differentiation of cultured hepatic stellate cells and of skin fibroblasts: (1) synthesis of collagens type I and III, the predominant collagens in fibrosis of liver and other organs; (2) cellular proliferation; and (3) expression of smooth muscle  alpha -actin, a marker for activated myofibroblasts. These results indicate that trichostatin A is a potent antifibrogenic agent, totally different from any other therapeutic compounds previously described.
Patent DE-69730517-D1 (DE)
Inventor: SIPILAE KARI
IPC: H04B17/00
Filed: 1997-12-17
Granted: 2004-10-07
Abstract: The invention relates to a method and an apparatus for calculating field strength in connection with buildings (102, 114) when an outdoor transmitter (106) is involved. To enable field strength determination preferably without heavy calculation procedures, the method comprises determining estimates of the electromagnetic field produced by the transmitter (106) on surfaces delimiting the building (104) or a part thereof, determining the field strength inside the building or a part thereof by means of the estimates of the electromagnetic field calculated for the surfaces delimiting the building or a part thereof. The method can be similarly applied when an indoor transmitter is involved.
Patent DE-69737496-D1 (DE)
Inventor: OEHRLEIN REINHOLD
IPC: C07H15/04
Filed: 1997-01-17
Granted: 2007-05-03
Abstract: Sialyl-Lewisx and sialyl-Lewisa epitope analogues in which the naturally occurring N-acetyl group of the N-acetylglucosamine monomer is replaced by various aliphatic or aromatic substituents and the L-fucose naturally present is replaced by various naturally occurring or non-naturally occurring sugars.
Patent DE-69739046-D1 (DE)
Inventor: HISERODT JOHN C
IPC: A61K39/00
Filed: 1997-07-25
Granted: 2008-11-27
Abstract: This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-alpha, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.
Patent DE-69739497-D1 (DE)
Inventor: CECH THOMAS R
IPC: C12N9/12
Filed: 1997-10-01
Granted: 2009-08-27
Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
Patent DE-69800604-D1 (DE)
Inventor: PEGLION JEAN-LOUIS
IPC: A61K31/165
Filed: 1998-04-06
Granted: 2001-04-26
Abstract: 7-Amino-6,7,8,9-tetrahydro-cyclopentaÄaÜnaphthalen-1-one derivatives of formula (I) and their racemates, optical isomers and acid addition salts are new. n = 0 or 1; Y = H, CH2W or a group of formula (a) or (b); W = H or 1-5C alkyl, 2-5C alkenyl or 2-5C alkynyl; p = 1-5; R1, R2 = H, halo, OH, 1-5C alkoxy, NHSO2Me, NHSO2CF3, NHCOMe, NHCOCF3 or CONR4R5; R4, R5 = H or 1-6C alkyl; m = 2-5; and R3 = H, halo, OH, 1-6C alkoxy, CF3, CN or phenyl.
Patent DE-69804215-D1 (DE)
Inventor: GUSTAFSSON ANDERS
IPC: A61F5/44
Filed: 1998-05-13
Granted: 2002-04-18
Abstract: An absorbent article with an absorbent body enclosed between inner and outer casing sheets and a stiffening element extending from the rear, through the intermediate, and into the front part of the article. The stiffening element's front and rear parts are broader than its intermediate part and the stiffening element is not wider than 4 cm at its front to intermediate transition region. Side flaps are formed by at least some parts of the remainder of the article which extend laterally beyond the stiffening element, so that the distance between side-edges of the stiffening element and an edge of the side flap varies within the region. The stretch resistance of the side flaps is greater than the stiffening element's longitudinal bending resistance, so inward pressing of the side flaps causes the stiffening element to curve longitudinally, to obtain an upwardly concave shape adapted to the shape of a wearer's body.